Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer StudyBusiness Wire • 04/28/25
Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence DetectionBusiness Wire • 04/22/25
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.Investors Business Daily • 04/17/25
Personalis to Participate at the 24th Annual Needham Virtual Healthcare ConferenceBusiness Wire • 03/26/25
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence DetectionBusiness Wire • 03/03/25
Personalis (PSNL) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 02/20/25
Personalis to Participate at the TD Cowen's 45th Annual Health Care ConferenceBusiness Wire • 02/18/25
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire • 01/28/25
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung CancerBusiness Wire • 01/13/25
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with ModernaBusiness Wire • 12/19/24